Uncategorized

Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on

Published

on

Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version